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Carrier-facilitated pyruvate transport across the
inner mitochondrial membrane plays an essential
role in anabolic and catabolic intermediary meta-
bolism. Mitochondrial pyruvate carrier 2 (Mpc2) is
believed to be a component of the complex that facil-
itates mitochondrial pyruvate import. Complete
MPC2 deficiency resulted in embryonic lethality in
mice. However, a second mouse line expressing an
N-terminal truncated MPC2 protein (Mpc2D16) was
viable but exhibited a reduced capacity for mito-
chondrial pyruvate oxidation. Metabolic studies
demonstrated exaggerated blood lactate concentra-
tions after pyruvate, glucose, or insulin challenge in
Mpc2D16 mice. Additionally, compared with wild-
type controls, Mpc2D16 mice exhibited normal insulin
sensitivity but elevated blood glucose after bolus
pyruvate or glucose injection. This was attributable
to reduced glucose-stimulated insulin secretion and
was corrected by sulfonylurea KATP channel inhibitor
administration. Collectively, these data are consis-
tent with a role for MPC2 in mitochondrial pyruvate
import and suggest that Mpc2 deficiency results in
defective pancreatic b cell glucose sensing.
INTRODUCTION
Pyruvate is an important three-carbon intermediate in energy
metabolism and is a central substrate in carbohydrate, fat, and
amino acid catabolic and anabolic pathways. Pyruvate is gener-
ated in the cytoplasm through glycolysis and subsequently is
transported into the mitochondrion for oxidation or carboxyla-
tion, which is required for several critical metabolic processes
(Figure 1A). For example, mitochondrial pyruvate carboxylation2042 Cell Reports 7, 2042–2053, June 26, 2014 ª2014 The Authorsin the mitochondrial matrix results in the formation of oxaloace-
tate (an anaplerotic reaction), which is required for the biosyn-
thesis of glucose via gluconeogenesis. Pyruvate entry into the
mitochondrial matrix is also required for pyruvate oxidation,
which is a prerequisite for the production of reducing equivalents
in the tricarboxylic acid (TCA) cycle and production of citrate for
de novo lipogenesis. Both pyruvate oxidation and carboxylation
are critical for glucose-stimulated insulin secretion (GSIS) in
pancreatic b cells (Jensen et al., 2008; Prentki et al., 2013;
Sugden and Holness, 2011). Elevated blood glucose causes an
increase in the intracellular ratio of ATP/ADP via increased mito-
chondrial pyruvate oxidation (Prentki et al., 2013; Sugden and
Holness, 2011). ATP inhibits KATP channels, leading to depolari-
zation, Ca2+ influx, and the release of insulin into the circulation
(Huopio et al., 2002). Anaplerotic mitochondrial pyruvate meta-
bolism activates pyruvate cycling pathways that alter NADPH,
and regulates insulin secretion by inhibiting KATP channel activity
as well (Jensen et al., 2008).
The existence of carrier-assisted transport of pyruvate across
the inner mitochondrial membrane (IMM) was demonstrated in
the 1970s (Halestrap, 1975; Halestrap and Denton, 1975; Papa
et al., 1971). However, the proteins that facilitate pyruvate import
into the mitochondrial matrix have only recently been identified
(Bricker et al., 2012; Herzig et al., 2012). New evidence has
emerged that the mitochondrial pyruvate carrier (MPC) is
composed of two proteins, MPC1 and MPC2, which form a
hetero-oligomeric complex in the IMM, and that both proteins
are required for complex activity and stability (Bricker et al.,
2012; Herzig et al., 2012). The MPC protein complex has been
determined to be essential for mitochondrial pyruvate transport
in Drosophila and yeast (Bricker et al., 2012; Herzig et al.,
2012). In humans, mutations in MPC1 have been identified and
associated with defects in mitochondrial pyruvate metabolism,
lactic acidosis, hyperpyruvatemia, severe illness, and failure to
thrive (Bricker et al., 2012; Brivet et al., 2003). Since its discovery,
interest in the MPC complex as a drug target for cancer, neuro-
logical disorders, and metabolic diseases has been extremely
Figure 1. MPC Proteins Are Highly Expressed in Tissues with High
Mitochondrial Content
(A) The schematic depicts an overview of mitochondrial pyruvate metabolism.
OMM, outer mitochondrial membrane; IMM, inner mitochondrial membrane;
PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase; OAA, oxaloace-
tate; TCA, tricarboxylic acid.
(B) Western blot depicting expression of the indicated proteins in
whole-cell lysates from various C57Bl/6 mouse tissues. Cytochrome c
(cyto c) is shown to demonstrate mitochondrial abundance in the whole-cell
lysates.
Chigh. Recent work suggests that insulin-sensitizing thiazolidine-
dione compounds bind the MPC complex (Colca et al., 2013)
and modulate mitochondrial pyruvate oxidation (Divakaruni
et al., 2013; Colca et al., 2013). Thus, a better understanding of
MPC function has the potential to advance our knowledge about
intermediary metabolism and impact drug discovery for current
public health problems.
Herein, we report the generation and characterization of two
MPC2-deficient mouse strains. Although complete MPC2 defi-
ciency resulted in embryonic lethality, mice expressing a trun-
cated, partially functional MPC2 protein were viable. Diminished
pyruvate metabolism led to elevated blood lactate concentra-
tions, particularly when mice were challenged with stimuli that
increased glucose metabolism. The mutant mice also exhibited
elevated blood glucose during glucose tolerance tests (GTTs)
and pyruvate tolerance tests (PTTs) that was likely due to
reduced GSIS. Additionally, glucose intolerance could be cor-
rected by administration of KATP channel-inhibiting sulfonylurea
drugs. These studies demonstrate the importance of mitochon-
drial pyruvate transport to glucose homeostasis in a mammalian
system and support the continued exploration of mitochondrial
function in complex metabolic diseases.
RESULTS
Tissue Expression of MPC Proteins
We first isolated various tissues fromC57BL/6mice to determine
relative Mpc mRNA and MPC protein expression. We detected
large variations in MPC protein (Figures 1B and 1C) and mRNA
expression (Figure 1D), with the highest levels observed in
tissues with greater mitochondrial abundance. Isolation and
equal loading of mitochondrial lysate from these tissues some-
what normalized MPC1 and MPC2 protein expression (Figures
S1A and S1B). However, MPC protein was still most abundant
in highly oxidative tissues even when corrected for mitochondrial
protein content.
Generation of Mpc2-Deficient Mice
We targeted the Mpc2 allele for deletion by using zinc-finger
nuclease (ZFN) technology. The first line of mice harbored a
deletion of 2 nt just downstream of the start codon (Figure S2A),
resulting in a frameshift mutation and likely complete loss of pro-
tein product (Mpc2/ mice). The mutation results in embryonic
lethality in homozygous embryos. However, the number of
heterozygous mice present at weaning was as predicted by
Mendelian ratios (p = 0.717; Table S1), and these mice were
overtly indistinguishable from their wild-type (WT) littermates.
Lethality in homozygous embryos likely occurs between embry-
onic day 11 (E11) and E13, a period when robust mitochondrial
biogenesis takes place (Ca´mara et al., 2011; Larsson et al.,(C) Quantified densitometry of the western blot shown in (B). Data are pre-
sented as mean ± SEM (n = 3 separate animals).
(D) Expression pattern of Mpc1 and Mpc2 in C57Bl/6 mice as measured by
qRT-PCR. Values are expressed as arbitrary units (AU) and presented as
mean±SEM (n=5separate animals). Br, brain;BAT, brownadipose tissue; Epi,
epididymal adipose tissue; PR, perirenal adipose tissue; Gas, gastrocnemius;
Sol, soleus; H, heart; Int, intestine; Kid, kidney; Liv, liver; Lu, lung; Spl, spleen.
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Figure 2. Generation of MPC2-Deficient Mice
(A) Western blot depicting the abundance of MPC1, MPC2, PC, and PDH
complex protein in mitochondrial lysates of various tissues fromMpc2D16 mice
and WT controls. VDAC1 is used as a loading control.
(B) The ability of WT MPC2 and MPC2D16 protein to coimmunoprecipitate
MPC1 was tested by using an antibody against the C terminus of MPC2 and
BAT mitochondrial lysates from WT and Mpc2D16 mice. Negative control
(irrelevant immunoglobulin G [IgG]) and input (nonprecipitated mitochondrial
lysates) are also shown for comparison.
(C) Western blots for MPC1 and MPC2 after subcellular fractionation to
separate cytosolic andmitochondrial fractions fromWT andMpc2D16 mice are
shown. LDH is used to demarcate the cytosolic fraction, and VDAC1 de-
marcates the mitochondrial fraction.
(D) Western blots after mitochondrial subfractionation to separate cytosolic,
OMM, IMM, andmatrix components by using liver fromWT andMpc2D16mice.
LDH demarcates the cytosolic fraction, cytochrome c oxidase subunit 4 (Cox4)
demarcates the IMM, and PC demarcates the matrix.
2044 Cell Reports 7, 2042–2053, June 26, 2014 ª2014 The Authors1998; Metodiev et al., 2009; Park et al., 2007). Timed mating
studies yielded expected Mendelian ratios at embryonic days
10 and 11 (p = 0.496; Table S2), but no viable homozygote
embryos at E13 (Table S3). Western blots of the tissues of
heterozygous (Mpc2+/) mice demonstrated only a modest
reduction in MPC2 and MPC1 protein compared with WT con-
trols (Figure S2B). Pyruvate-driven oxygen consumption by iso-
lated mitochondria from Mpc2+/ mice was not diminished
compared with WT mitochondria (Figure S2C).
A second attempted knockout strategy resulted in the deletion
of 20 nt including the original start codon for MPC2 translation.
Despite the deletion, Mpc2 mRNA was expressed at normal
levels (data not shown) and MPC2 protein translation proceeded
from a second downstream start codon (Figure S2A). This
resulted in a truncated protein that lacked the first 16 amino
acids residues of the N terminus (MPC2D16). Pups homozygous
for the truncated allele were born at the expected Mendelian
ratios (p = 0.995; Table S1) and were outwardly normal. The trun-
cated protein, detected by western blotting with an antibody
against the C terminus of MPC2, was less abundant than the
WT protein in all tissues examined, except for brown adipose tis-
sue (BAT; Figure 2A). The Mpc2D16 mutation led to a marked
reduction in the abundance of MPC1 protein, likely reflecting
the maintenance of a stoichiometric ratio of MPC1 and MPC2
protein in the complex. Immunoprecipitation studies also indi-
cated that the Mpc2D16 mutant protein coimmunoprecipitated
less MPC1 protein, suggesting that the interaction between the
two proteins is significantly weakened by the loss of these 16
amino acids of MPC2 (Figure 2B). The abundance of the pyru-
vate dehydrogenase (PDH) complex and pyruvate carboxylase
(PC) proteins was not altered in various tissues of the Mpc2D16
mice, suggesting a lack of significant downstream alterations
in pyruvate metabolic enzymes (Figure 2A). Western blotting of
subfractionated kidney and heart demonstrated that the trun-
cated Mpc2D16 protein properly localized to mitochondria (Fig-
ure 2C) and specifically to the IMM in liver (Figure 2D).
Isolated Mpc2D16 Mitochondria Have Reduced Oxygen
Consumption
The Mpc2D16 mice were healthy and appeared outwardly
normal, suggesting that the MPC complex was at least partially
functional. Plasma triglyceride was decreased and plasma
ketone concentrations were increased in Mpc2D16 mice com-
pared with WT control mice (Table 1), suggesting an increased
reliance on fat oxidation. Possibly consistent with a reduced
capacity for mitochondrial pyruvate import, blood lactate con-
centrations were also significantly elevated (Table 1).
Therefore, we evaluated the effects of the MPC2 truncation
on oxygen consumption in isolated mitochondria. We used
heart and kidney tissue due to their high mitochondrial
density and high MPC expression. Mpc2D16 mitochondria from
heart or kidney exhibited 25%–30% lower rates of pyruvate/
malate-stimulated respiration in 2,4-dinitrophenol (DNP)-
uncoupled conditions compared with WT controls (Fig-
ure 3A). Addition of methyl-pyruvate, a membrane-permeable
pyruvate analog, rescued oxygen consumption to WT levels in
Mpc2D16 mitochondria. Additionally, maximal oxygen consump-
tion rates in Mpc2D16 mitochondria with glutamate/malate or
Table 1. Baseline Plasma Parameters
WT MPC2D16
Glucose (mg/dl) 125.1 ± 5.7 124.3 ± 5.1
Lactate (mmol/l) 1.6 ± 0.09 2.3 ± 0.11a
Insulin (ng/ml) 0.51 ± 0.09 0.34 ± 0.03
Triglyceride (mg/dl) 61.8 ± 2.2 54.8 ± 1.9a
NEFA (mmol/l) 0.58 ± 0.05 0.67 ± 0.05
Cholesterol (mg/dl) 65.3 ± 2.6 58.3 ± 3.7
Total ketones (mmol/l) 0.15 ± 0.01 0.25 ± 0.01a
ap < 0.05 versus WT. Data are expressed as mean ± SEM.succinate/rotenone were unaltered compared with WT controls.
Together, these data suggest a specific effect of the Mpc2D16
mutation on mitochondrial pyruvate oxidation.
Mitochondrial Membrane Potential Is Normal
in Fibroblasts from Mpc2D16 Mice
Given the observed defect in pyruvate oxidation in Mpc2D16
tissues, we investigated whether these mitochondria displayed
any sign of overt dysfunction by assessing the mitochondrial
membrane potential (DJM) in isolated adult fibroblasts of WT
and Mpc2D16 mice. Tetramethylrhodamine, ethyl ester, perchlo-
rate (TMRE) staining revealed no difference in DJM, a compre-
hensive measure of overall mitochondrial function, in Mpc2D16
fibroblasts compared with WT controls (Figure 3B). The lack of
effect on mitochondrial membrane potential was likely due toCthe small decrease in pyruvate-stimulated respiration and the
maintained ability to metabolize other substrates.
Exercise Endurance Is Normal in MPC2D16 Mice
During exercise, significant quantities of pyruvate, which is inter-
converted to lactate, are generated via anaerobic glycolysis in
skeletal muscle. Lactate, transported by the blood to the liver,
is converted back to glucose that can again be used anaerobi-
cally as an energy source in muscle. This process, known as
the Cori cycle (Katz and Tayek, 1999; Pilkis et al., 1988), depends
on pyruvate import in liver mitochondria. Therefore, we chal-
lenged Mpc2D16 homozygote and Mpc2+/ mice using an acute
endurance exercise bout of gradually increasing intensity until
exhaustion (Figure 3C). The average blood glucose concentra-
tion of the Mpc2D16 mice was not different from that of WT con-
trols in the 60 min after exercise (Figure 3C). However, the
average blood lactate of the Mpc2D16 was approximately 2-fold
higher compared with WT controls immediately after exercise
and remained significantly elevated for 30 min postexercise (Fig-
ure 3C). Postexercise blood lactate and glucose concentrations
were not different between Mpc2+/ and WT mice (Figure 3C).
Despite the robust differences in blood lactate concentrations
postexercise, we observed no significant differences in acute
endurance exercise capacity among the genotypes (Figure 3C).
Elevated Blood Glucose and Lactate in Mpc2D16 Mice
following Pyruvate Injection
To test the effects of the Mpc2 mutations on pyruvate
disposal in vivo, we subjected Mpc2D16 homozygotes andFigure 3. Mpc2D16 Mice Have a Diminished
Capacity for Pyruvate Utilization, but
Exercise Capacity Is Unimpaired
(A) DNP-stimulated rates of oxygen consumption
by mitochondria isolated from heart or kidney of
WT or Mpc2D16 mice in the presence of the
indicated substrates (n = 8).
(B) TMRE staining of tail fibroblasts isolated from
WT or Mpc2D16 mice (n = 8, separate experiments
in duplicate).
(C) Schematic of the exercise protocol. Shown are
blood glucose and blood lactate curves for WT,
Mpc2+/, and Mpc2D16 mice following graduated-
intensity exercise on a motor-driven treadmill
(n = 6), and elapsed time until exhaustion for WT,
Mpc2+/, and Mpc2D16 mice during graduated-
intensity exercise (n = 6). Data are presented
as mean ± SEM. *p < 0.05, Mpc2D16 versus WT.
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Figure 4. Mpc2D16 Mice Have Elevated
Blood Glucose and Blood Lactate during
a PTT, but Gluconeogenesis Remains
Unimpaired
(A) Blood glucose and blood lactate curves for
WT, Mpc2+/, and Mpc2D16 mice during i.p. PTT
(n = 14).
(B) 13C enrichment of plasma glucose isotopomers
and total 13C-labeled plasma glucose.
(C) 13C enrichment of plasma lactate isotopomers
and total 13C-labeled plasma lactate (n = 7).
(D) Expression of liver gluconeogenesis enzymes.
(E) Plasma insulin 15 min after bolus pyruvate
injection. Data are presented as mean ± SEM. *p <
0.05, **p < 0.01 Mpc2D16 versus WT.Mpc2+/ mice to an intraperitoneal (i.p.) PTT. Following pyru-
vate injection, blood lactate increased 5-fold in all groups.
However, the decline in blood lactate concentration was
significantly slower in Mpc2D16 mice compared with WT con-
trols (Figure 4A). Blood glucose and lactate levels were not
different between Mpc2+/ and WT mice. Compared with2046 Cell Reports 7, 2042–2053, June 26, 2014 ª2014 The AuthorsWT mice, Mpc2D16 mice also exhibited
a significantly greater blood glucose
excursion (Figure 4A). These data are
consistent with reduced pyruvate utiliza-
tion resulting in elevated blood lactate
concentrations.
To specifically evaluate the effect
of the Mpc2D16 mutation on pyruvate
gluconeogenesis and other intracellular
pathways of pyruvate metabolism, we
repeated the pyruvate challenge in
Mpc2D16 mice with uniformly labeled
[U-13C]pyruvate. The mice were sacri-
ficed, plasma and tissue were collected
60 min postinjection, and fractional 13C
enrichments were evaluated by mass
spectrometry. There were no differ-
ences in hepatic oxaloacetate, malate,
or fumarate concentrations or enrich-
ments (Figure S3), indicating that liver
mitochondrial pyruvate anaplerosis is
intact in Mpc2D16 mice. Although the
fractional enrichment of plasma glucose
was unaffected by the Mpc2D16 muta-
tion (Figure 4B), the plasma glucose
concentration and therefore the total
amount of 13C-labeled plasma glucose
were significantly elevated in Mpc2D16
mice versus WT mice (Figure 4B).
These data suggest that the capacity
for pyruvate-derived gluconeogenesis
is intact in Mpc2D16 mice. Incorporation
of 13C-label into plasma lactate was not
different between Mpc2D16 and WT
control groups (Figure 4C). However,due to the increased lactate concentration in the blood,
13C-labeled plasma lactate was significantly elevated in
Mpc2D16 mice compared with WT controls (Figure 4C),
consistent with decreased mitochondrial pyruvate metabolism
in extrahepatic tissues. Additionally, expression of liver gluco-
neogenic enzymes was unaltered in Mpc2D16 mice, except
Figure 5. Mpc2D16 Mice Are Responsive to
Insulin, but Are Glucose Intolerant and
Hypoinsulinemic
(A) Blood glucose and blood lactate curves for WT
andMpc2D16 mice during i.p. ITT (n = 14). Data are
presented as mean ± SEM. *p < 0.05, **p < 0.01
Mpc2D16 versus WT.
(B) Western blot and quantified densitometry
of liver S473-AKT phosphorylation 15 min after
insulin injection.
(C) Western blot and quantified densitometry of
gastrocnemius S473-AKT phosphorylation 15 min
after insulin injection.
(D) Blood glucose and blood lactate curves for WT
and Mpc2D16 mice during an i.p. GTT (n = 15).
(E) Plasma insulin from blood collected during an
i.p. glucose challenge (n = 9). Data are presented
as mean ± SEM. *p < 0.05, **p < 0.01 Mpc2D16
versus WT.that Pck2, which encodes the mitochondrial form of phos-
phoenolpyruvate carboxykinase, was significantly decreased
(Figure 4D), suggesting that compensatory activation of these
genes does not explain the intact gluconeogenic flux. Alto-
gether, these data suggest that hepatic gluconeogenesis is
not impaired in Mpc2D16 mice.
Mpc2D16 Mice Are Sensitive to Insulin, but Have
Reduced Plasma Insulin and Elevated Blood Glucose
One possible explanation for the elevated blood glucose con-
centration in the PTT studies is that Mpc2D16 mice are insulin
resistant. We conducted insulin tolerance tests (ITTs) to
examine insulin effectiveness. Although blood lactate during
the ITT was significantly elevated in Mpc2D16 mice compared
with WT mice, blood glucose concentrations at all time points
and the area under the curve (AUC) were not different, sug-Cell Reports 7, 2042–205gesting that insulin-stimulated glucose
disposal is normal in Mpc2D16 mice
(Figure 5A). Insulin-stimulated phos-
phorylation of Akt in liver was signifi-
cantly enhanced (Figure 5B) and was
unaltered in gastrocnemius muscle (Fig-
ure 5C) of Mpc2D16 mice compared
with WT control mice. These data
suggest that the Mpc2D16 mice have
normal sensitivity to the effects of
insulin.
In contrast, Mpc2D16 mice exhibited
elevated blood lactate and trended to-
ward a higher glucose AUC (p = 0.078)
during an i.p. GTT (Figure 5D). Plasma
insulin concentration was significantly
lower in Mpc2D16 mice compared with
WT controls at baseline and 30 min
after glucose injection (Figure 5E), sug-
gesting that glucose intolerance in
Mpc2D16 mice was due to insufficient
insulin secretion. Similarly, blood insulin
concentration in Mpc2D16 mice com-pared with WT controls was also significantly lower 15 min af-
ter a bolus pyruvate injection (Figure 4E).
Impaired GSIS in Mpc2D16 Mice Is Corrected by
Glibenclamide
The data obtained in GTT studies suggested a defect in GSIS
by pancreatic islet b cells of Mpc2D16 mice. Both MPC1 and
MPC2 are expressed in b cells, as demonstrated by colocal-
ization with insulin in immunohistochemical staining of
pancreatic sections (Figure 6A). Western blotting analyses
confirmed that MPC1 and MPC2 proteins are expressed in
isolated pancreatic islets and demonstrated that the expres-
sion of the MPC2D16 protein was markedly reduced
compared with WT MPC2 (Figure 6B). Islet insulin content
in Mpc2D16 mice was not different from that in WT controls
(Figure 6C).3, June 26, 2014 ª2014 The Authors 2047
Figure 6. Elevated Blood Glucose and Defective GSIS in Mpc2D16 Mice Are Corrected by Glibenclamide Treatment
(A) Images from immunofluorescent staining of pancreatic islets fromC57Bl/6micewith antibodies againstMPC1 (green),MPC2 (green), or insulin (red) are shown.
(B) Western blot depicting the abundance of MPC2 and MPC1 protein using protein lysates from isolated islets from Mpc2D16 mice and WT controls.
(C) Insulin content of islets isolated from WT and Mpc2D16 mice (n = 6).
(D) Insulin secretion by isolated pancreatic islets from WT and Mpc2D16 mice in response to the indicated stimuli (n = 6).
(E) Blood glucose and blood lactate curves during an i.p. GTT for WT and Mpc2D16 mice treated with glibenclamide or saline vehicle (n = 11–13).
(F) Plasma insulin from blood collected during the experiment described in (E) (n = 11–13). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01 Mpc2D16
versus WT.
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We examined GSIS in isolated pancreatic islets from WT and
Mpc2D16 mice. Compared with WT islets, Mpc2D16 islets ex-
hibited reduced insulin secretion in response to 23 mM glucose
(Figure 6D). b cell glucose sensing requires mitochondrial
pyruvate metabolism, resulting in closure of the KATP channels
(Huopio et al., 2002).We therefore examined the effects of gliben-
clamide, a sulfonylurea drug that inhibits KATP channel activity, on
GSIS inMpc2D16 islets. Aswehypothesized, theGSISdefectwas
rescued by the addition of glibenclamide to high-glucose media
(Figure 6D). Additionally, Mpc2D16 islets exhibited normal insulin
secretion in response to KCl (Figure 6D). Supplementing high-
glucose medium with glutamine, a metabolic substrate that
does not require the MPC complex to enter the mitochondrion
to be oxidized, also corrected the defect in GSIS (Figure 6D).
These findings collectively suggest that the Mpc2D16 insulin
secretion defect is specific to stimulation by mitochondrial pyru-
vate metabolism rather than to a general deficiency in insulin
production or defects in the insulin secretory machinery.
To confirm the relevance of these findings in vivo, we adminis-
tered glibenclamide to Mpc2D16 mice with a bolus of glucose in
GTT studies. Vehicle-treated Mpc2D16 mice exhibited elevated
blood glucose concentrations compared with WT mice at 30
and 60 min postinjection, but blood glucose concentrations in
Mpc2D16 mice treated with glibenclamide were not different
from those in vehicle-treated WT mice (Figure 6E). Administra-
tion of glibenclamide did not affect plasma lactate concentra-
tions in mice of either genotype. Glibenclamide administration
toMpc2D16 mice resulted in increased plasma insulin concentra-
tions, which were reduced in Mpc2D16 mice versus WT mice, at
15 and 30 min after injection (Figure 6F). These data further sup-
port the model in which whole-body Mpc2 deficiency leads to a
defect in GSIS that is improved by KATP channel inhibition.
DISCUSSION
Carrier-mediated transport of pyruvate across the IMM is a crit-
ical step in intermediary metabolism, which is required for both
anaplerotic and cataplerotic mitochondrial pyruvate meta-
bolism. We found that complete loss of MPC2 led to embryonic
lethality, but expression of a truncated MPC2 protein that
exhibited hypomorphic activity was sufficient to support life.
The most striking phenotypes of the Mpc2D16 mice were
elevated plasma lactate concentrations, particularly in the
context of increased glucose concentrations, and a defect in b
cell GSIS leading to relative glucose intolerance. These findings
are consistent with a function for MPC2 in regulating mitochon-
drial pyruvate utilization and reveal important roles for MPC2 in
regulating whole-body glucose homeostasis.
As mitochondrial pyruvate import is required in a number of
critical metabolic pathways, it was not unexpected that com-
plete ablation of Mpc2 resulted in embryonic lethality. Human
mutations in MPC1 are associated with neonatal and juvenile
mortality (Brivet et al., 2003). We were unable to recover viable
Mpc2/ embryos after E11, which is when mitochondrial func-
tion begins to play a larger role in embryonic metabolism
(Ca´mara et al., 2011; Larsson et al., 1998; Metodiev et al.,
2009; Park et al., 2007). Mpc2+/ mice exhibited only a modest
reduction in MPC2 and MPC1 protein abundance, and wereCphenotypically indistinguishable from WT littermates in every
parameter we examined. Our inability to detect a phenotype
from the Mpc2+/ mice, even under conditions of metabolic
challenge, likely highlights an excess transport capacity of the
MPC complex.
We also serendipitously created a truncated mutant MPC2
protein as a consequence of the unpredictable results obtained
by ZFN-mediated deletion. Although the Mpc2D16 mutant has a
nucleotide deletion larger than that of the Mpc2/ mouse
(20 bp versus 2 bp, respectively), it utilizes a downstream methi-
onine as an alternative start site for translation of a truncated
MPC2 protein. Because the original start codon is ablated by
the 20 bp deletion but is intact in the 2 bp deletion, this allows
an alternative ribosomal entry sequence to be enforced. This
start codon may be less efficient or the resulting protein less
stable, given that MPC2D16 protein is less abundant than full-
length MPC2. Most tissues in the Mpc2D16 mice also had a
significant reduction in abundance of the MPC1 protein. Previ-
ous work has shown that MPC1 and MPC2 must be coex-
pressed for proper assembly of the multimeric MPC complex,
and that depletion of either protein leads to reduced abundance
of the other (Bricker et al., 2012; Colca et al., 2013). It is likely that
the reduced abundance of MPC1 in the Mpc2D16 mice is due to
the lower quantity of Mpc2D16 compared with WT protein. A
diminished or weakened protein-protein interaction between
the two proteins is also a potential factor in the reduced complex
stability, since less MPC1 was coimmunoprecipitated with
MPC2D16 compared with WT protein. However, the expression
of MPC1 was only modestly affected by MPC2 truncation in
BAT and islets, suggesting a tissue-specific regulation of MPC
complex stability or the possible existence of homodimeric
MPC protein complexes.
The truncated MPC2 protein is properly localized to the IMM
and presumably, based on the phenotypes of the mutant mice,
forms a transporter complex that is functionally hypomorphic.
A number of mitochondrial carrier proteins of the IMM do not uti-
lize canonical N-terminal mitochondrial localization sequences
(Ferramosca and Zara, 2013; Pfanner andGeissler, 2001; Harba-
uer et al., 2014). Instead, these carriers utilize internal sequences
that that have yet to be defined. Indeed, analysis by mitochon-
drial localization prediction programs, which predict mitochon-
drial targeting based on these canonical N-terminal localization
sequences, did not produce a high-scoring prediction of mito-
chondrial localization for full-length or D16 MPC2 protein. How-
ever, the focus of this paper was not to define the targeting
sequence, because that has been elusive for most mitochondrial
proteins that lack the N-terminal canonical sequence.
Given that conversion of pyruvate into glucose by liver and
kidney requires pyruvate to enter mitochondria for conversion
to oxaloacetate, we expected that the Mpc2D16 mice might be
hypoglycemic in conditions requiring gluconeogenesis. Previous
work using isolated liver preparations and a chemical inhibitor of
MPC activity showed an acute inhibition of hepatic glucose
output (Martin-Requero et al., 1986; Rognstad, 1983; Thomas
and Halestrap, 1981). However, whether carrier-mediated pyru-
vate transport by MPC plays a significant role in controlling
gluconeogenesis has been debated (Groen et al., 1983, 1986;
Halestrap and Armston, 1984), and the hypomorphic functionell Reports 7, 2042–2053, June 26, 2014 ª2014 The Authors 2049
of theMPC transport complex was not a limiting factor in the glu-
coneogenic capacity of Mpc2D16 mice. Plasma 13C-labeled
glucose levels were actually increased in [U-13C]PTT studies
and Mpc2D16 mice were not hypoglycemic following exhaustive
exercise, suggesting that the Cori cycle was intact. The observa-
tion that gluconeogenesis was not impaired is not entirely
unprecedented, given that previous studies have shown that
an up to 85% reduction in phosphoenolpyruvate carboxykinase
expression does not impact gluconeogenic flux (Burgess et al.,
2007). Further work with other, more complete, liver-
specific loss-of-function models will be needed to define the
role that MPC complex proteins play in regulating hepatic
gluconeogenesis.
Another interesting phenotype of the Mpc2D16 mice was the
hyperglycemia detected during PTT and GTT studies. Given
that the insulin-stimulated decrease in blood glucose concentra-
tion was normal in ITT experiments and pyruvate metabolism is
important for b cell glucose sensing (Lu et al., 2002; Prentki
et al., 2013; Sugden andHolness, 2011), we suspected that insu-
lin secretion might be defective. Indeed, plasma insulin concen-
tration was diminished in Mpc2D16 mice compared withWTmice
during the GTT and PTT studies, and isolated islets from
Mpc2D16 mice exhibited an attenuated insulin secretion
response following the administration of 23 mM glucose.
Glucose sensing and GSIS require mitochondrial pyruvate
oxidation and carboxylation. b cells express very little lactate
dehydrogenase (LDH), and most of the pyruvate generated
from glycolysis enters the mitochondrion for further metabolism
(Malmgren et al., 2009; Schuit et al., 1997). Pyruvate carboxyla-
tion and oxidation inhibit ATP-sensitive potassium channels
(KATP), depolarizing the b cell membrane, opening voltage-
dependent calcium channels, and triggering the release of
insulin into the circulation (Huopio et al., 2002). We found that
the defects in insulin secretion by isolated islets and hypoinsuli-
nemia/hyperglycemia in Mpc2D16 mice were corrected by the
sulfonylurea glibenclamide, which functions by binding and
inhibiting the regulatory subunit of KATP channels. It is likely
that glibenclamide is able to circumvent the reduced capacity
of Mpc2D16 mutants for mitochondrial pyruvate metabolism.
The observation that glutamine, which relies upon its own IMM
carrier (Indiveri et al., 1998), is able to stimulate insulin secretion
in Mpc2D16 islets also supports the notion of a specific defect in
mitochondrial pyruvate metabolism. Consistent with these data,
while this paper was in review, Patterson et al. (2014) used chem-
ical inhibitors and small interfering RNA (siRNA) methods to sug-
gest that MPC inhibition suppressed pyruvate metabolism and
GSIS in isolated islets and b cell lines. Taken together, these
studies demonstrate that the hypoinsulinemia of Mpc2D16 mice
is a specific defect in GSIS and not a broader indication of b
cell dysfunction.
The molecular identification of MPC proteins has stimulated
interest in targeting this complex for the treatment of many
chronic disease states. Pharmacologic approaches to modulate
the activity of the MPC complex could yield treatments for broad
categories of obesity-related metabolic diseases, neurodegen-
erative conditions, and neoplastic diseases associated with
impaired pyruvate metabolism (Constantin-Teodosiu, 2013;
Schell and Rutter, 2013; Stacpoole, 2012). For example, the2050 Cell Reports 7, 2042–2053, June 26, 2014 ª2014 The AuthorsMPC complex has recently been identified as a binding site for
the thiazolidinedione class of insulin sensitizers (Colca et al.,
2013), which acutely modulate mitochondrial pyruvate oxidation
(Divakaruni et al., 2013; Colca et al., 2013). The extent to which
regulation of mitochondrial pyruvate import by thiazolidine-
diones affects insulin sensitization remains unclear, but could
be addressed by MPC loss-of-function mouse models. Screens
to identify small molecules that enhance, inhibit, or selectively
modulate MPC activity may identify novel therapeutics with
applicability to myriad chronic diseases.
EXPERIMENTAL PROCEDURES
Animal Studies
Unless otherwise noted, all experiments were conducted with 10- to 16-week-
old female mice generated and maintained in a pure C57BL/6 background. All
animal experiments were approved by the Animal Studies Committee of
Washington University School of Medicine.
Generation of Mpc2-Deficient Mice
Mpc2 transgenic mice were generated by SAGE Labs using ZFN targeting
technology (Geurts et al., 2009). Specifically, the target site sequence was
TCCCTAGGCCGCCGCGATggcagCTGCCGGCGCCCGAGGCC (NCBI Ref
Seq: NC_000067.5. Exon 1, nucleotides 199–203). ZFN pairs were microin-
jected into C57BL/6 zygotes and transferred to pseudopregnant C57BL/6
females at 0.5 days postcoitum.
Western Blotting
PAGE was performed on protein lysates utilizing Criterion precast gels
(BioRad). Whole-cell lysates from tissue or cell culture were collected in
HNET buffer containing protease and phosphatase inhibitors. For blots of
mitochondrial lysates, mitochondria were obtained by differential centrifuga-
tion and solubilized in HNET buffer containing protease and phosphatase
inhibitors. Blots on isolated pancreatic islets involved isolation of islets as
described below, and 50 islets solubilized in 53 gel loading buffer per lane.
For immunoprecipitation, 250 mg of BAT mitochondrial lysates was solubilized
in lysis buffer containing 0.2% NP-40 and 10% glycerol. The lysates were pre-
cleared with 50 ml protein A beads and then incubated overnight with a rabbit
MPC2 antibody (a gift from Michael Wolfgang). Protein A beads (50 ml) were
then added 1 hr prior to immunoprecipitation. Liver mitochondrial fractionation
was conducted as previously described (Benga et al., 1979) with slight modi-
fication. In brief, digitonin-treated mitochondria were centrifuged at 9,5003 g.
The digitonin supernatants were centrifuged at 100,0003 g to isolate the outer
membrane pellet (OMM) and the supernatant containing the inner membrane
space. The digitonin pellet was loaded onto a discontinuous sucrose gradient
to generate mitoplasts. The mitoplasts were treated with Lubrol WX and the
IMM fractions were recovered from 100,0003 g discontinuous sucrose gradi-
ents. The antibodies utilized were b-Actin (Sigma-Aldrich), Akt (Cell Signaling
Technology), pS473-Akt (CST), CoxIV (CST), cytochrome c (Abcam), LDH
(Abcam), MPC1 and MPC2 (gifts from Michael Wolfgang), PC (Santa Cruz),
PDH cocktail (Abcam), a-tubulin (Sigma), and voltage-dependent anion chan-
nel (VDAC; Abcam).
Quantitative PCR and RT-PCR
Total RNA was isolated using the RNAzol method (Tel-Test). Real-time PCR
was performed using the ABI PRISM 7500 sequence detection system
(Applied Biosystems) and the SYBR Green kit. Arbitrary units of target
mRNA were corrected by measuring the levels of 36B4 RNA. The sequences
of the oligonucleotides used in quantitative PCR (qPCR) analyses are listed
in Table S4.
Measurement of Mitochondrial Respiration
Mitochondria from heart and kidney were isolated by differential centrifuga-
tion. High-resolution respirometry was conducted using a two-chamber
Oxygraph O2k (Oroboros Instruments). We added 200 mg of mitochondria to
2 ml respiration buffer for each substrate trace. The respiratory substrates uti-
lized were (concentration in mM) pyruvate (5)/malate (2), methyl-pyruvate (20)/
pyruvate (5)/malate (2), glutamate (10)/malate (2), and succinate (10) + 1 mM
rotenone. During pyruvate-stimulated respiration, 2 mM dichloroacetic acid
was added to stimulate PDH (Divakaruni et al., 2013). After substrate addition
and measurement of basal respiration, maximally stimulated, uncoupled
respiration was measured by addition of 2 mg/ml oligomycin and 10 mM DNP.
Isolation of Adult Murine Fibroblasts and Measurement of
Mitochondrial Membrane Potential
Isolation of primary adult murine fibroblasts from tail clip was performed as
previously described (Huss et al., 2004). Fibroblasts from WT and Mpc2D16
mice were cultured in high-glucose Dulbecco’s modified Eagle’s medium sup-
plemented with 20% fetal bovine serum. Cells were plated onto four-well glass
chamber slides (Lab-Tek II) at a density of 30,000 cells/well and incubated
overnight. The cells were then stained with 100 nM TMRE in Hank’s balanced
salt solution (HBSS) for 30min, washed with HBSS, and imaged on an inverted
fluorescence microscope (Nikon Instruments). The average TMRE fluores-
cence per cell was determined with ImageJ (NIH).
Acute Exercise Protocol
WT, Mpc2D16, and Mpc2+/mice performed a single bout of treadmill exercise
to exhaustion. The mice were fasted for 4 hr prior to the exercise session.
Following a 3 min familiarization period on the treadmill, the exercise protocol
consisted of graduated intensity running at 5 m/min for 5 min, 10 m/min for
5 min, 15 m/min for 10 min, 25 m/min for 15 min, and 30 m/min until the mouse
fatigued. The mice were encouraged to run with a mild electric stimulus (20 V)
positioned at the end of the treadmill and were determined to be exhausted by
their refusal to remain on the treadmill belt for 5 s. Postexercise blood glucose
and lactate levels were determined at 0, 5, 10, 20, 30, 60, and 120 min after
exhaustion.
Measurement of Baseline Plasma Parameters
Mice were fasted for 4 hr and tail blood glucose and lactate concentrations
were determined using aOne-Touch Ultra glucometer (LifeScan) and a Lactate
Plus lactate meter (Nova Biomedical), respectively. Blood samples for plasma
analyses were collected by mandibular bleeding. Plasma insulin was
measured with an ultrasensitive ELISA (Crystal Chem). Plasma triglyceride
and cholesterol concentrations were measured by Infinity assay kits (Thermo
Fisher Scientific). Nonesterified fatty acids (NEFAs) and total ketone concen-
trations were measured using enzymatic assays (Wako Diagnostics).
GTT, PTT, and ITT
For the GTT and PTT, mice were fasted overnight for 16 hr and housed on
aspen chip bedding. The mice were injected i.p. with 1 g/kg body weight
glucose or with 2 g/kg body weight Na-pyruvate dissolved in sterile physiolog-
ical saline. For the ITT,micewere fasted for 6 hr and injected i.p. with 0.75 U/kg
body weight insulin. Tail blood glucose and lactate concentrations were deter-
mined at 0, 30, 60, and 120 min after challenge as described above. The total
AUC was calculated using the trapezoidal rule. Blood samples for plasma
insulin quantification were collected by mandibular bleeding as described
above. A subset of mice were injected i.p. with 2 g/kg body weight Na-
pyruvate and sacrificed at 15 min to determine plasma insulin concentrations
during pyruvate challenge. To examine insulin-stimulated protein phosphory-
lation, a subset of mice were injected i.p. with 10 mU/g body weight human
insulin 15 min before sacrifice to collect liver and muscle tissue.
The glibenclamide rescue studies were conducted in the context of a
standard GTT, with sample time points adjusted to 0, 15, 30, and 60 min after
challenge. Glibenclamide was administered at 0.1 mg/kg body weight in a
glucose solution that contained 0.1% DMSO. Blood was collected at each
time point by means of mandibular bleeding as described above.
13C-Labeled Pyruvate Studies
Pyruvate labeling studies were conducted as previously described (Me´ndez-
Lucas et al., 2013). Briefly, mice were fasted for 16 hr and injected i.p. with
2 g pyruvate per kg body weight with a 10% enrichment of uniformly labeled
[U-13C3]Na-pyruvate (Cambridge Isotope Laboratories). The mice were sacri-Cficed at 60 min postinjection and plasma was analyzed by gas chromatog-
raphy-mass spectrometry as previously described (Sunny and Bequette,
2010).
Pancreas Immunohistochemistry
Protein expression of MPCs in pancreatic islets was determined in paraffin-
embedded pancreatic sections fromWTmice cut onto glass slides. The slides
were rehydrated, permeabilized with trypsin, blocked in 1% BSA, and probed
with guinea pig anti-insulin (Abcam) and either rabbit anti-MPC1 or rabbit anti-
MPC2 (gifts fromMichael Wolfgang). All antibodies were diluted 1:200 in buffer
containing 1% BSA and incubations were conducted overnight. The sections
were then washed three times for 5 min in PBS and probed with 1:1,000
donkey anti-rabbit green or 1:1,000 donkey anti-guinea pig red Alexa Fluor
secondary antibodies (Invitrogen) for 2 hr. The slides were again washed three
times for 5 min in PBS, mounted with Vectashield + DAPI, and imaged on an
epifluorescence microscope (Nikon Instruments).
Islet Isolation and Insulin Release Experiments
Islet isolation and insulin release studies were performed as previously
described (Remedi et al., 2004). Briefly, after the mice were euthanized, the
pancreases were removed and injected with HBSS (Sigma) containing colla-
genase (0.5 mg/ml, pH 7.4). They were digested for 4 min at 37C, and the
islets were isolated by hand. Following overnight incubation in 3 mM glucose
CMRL-1066 medium, islets (10 per well in 12-well plates) were incubated for
60 min at 37C in CMRL-1066 + 1 mM glucose, 23 mM glucose, 23 mM
glucose + 1 mM glibenclamide, 1 mM + 30 mM KCl, or 23 mM glucose +
10 mM glutamine, as indicated. After the incubation period, the medium was
removed and assayed for insulin release. Experiments were repeated in tripli-
cate. To estimate the islet insulin content, groups of ten islets were disrupted
by ethanol-HCl extraction and sonicated on ice. Insulin secretion and content
were measured using a rat insulin radioimmunoassay (Millipore) according to
the manufacturer’s instructions.
Statistical Analyses
Statistical comparisons were made using ANOVA, chi-square test, or t test. All
data are presented as means ± SEM, with a statistically significant difference
defined as p < 0.05.
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